Drugs / Pyrvinium Pamoate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05055323 | Jul 2021 → Aug 2024 overdue | in situ carcinoma, pancreatic ductal adenocarcinoma | Thomas Jefferson University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyrvinium Pamoate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05055323 ↗ |
| Route | Oral | “pyrvinium pamoate orally (PO)” NCT05055323 ↗ |